Name of journal: *World Journal of Medical Genetics*

ESPS Manuscript NO: 14243

Columns: REVIEW

**Cell mediated gene therapy: A guide for doctors in the clinic**

Noh MJ *et al.* Cell mediated gene therapy

Moon Jong Noh, Ogden Copeland, Michael O’Mara, Kwan Hee Lee

**Moon Jong Noh, Ogden Copeland, Michael O’Mara and Kwan Hee Lee,** TissueGene Inc., Rockville, MD 20850, United States

**Author contributions:** Noh MJ wrote most of this paper and gave input on the molecular aspect of TG-C; Copeland O reviewed and wrote the FDA related aspects; O’Mara M wrote the manufacturing part; Lee KH selected the review papers, decided the contents of the paper.

**Conflict-of-interest:** All of the authors are employees of TissueGene Inc. TissueGene Inc. will pay the fees for publication and editing of this paper. TissueGene Inc. owns the patent rights to protect the commercialization of TG-C.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Kwan Hee Lee, MD, PhD, Chief Medical Officer,** TissueGene Inc., 9605 Medical Center Drive, #200, Rockville, MD 20850, United States. ortholee@tissuegene.com

**Fax:** +1-301-9216011

**Received:** September 25, 2014

**Peer-review started:** September 28, 2014

**First decision:** November 27, 2014

**Revised:** January 6, 2015

**Accepted:** Janurary 15, 2015

**Article in press:**

**Published online:**

**Abstract**

The recent approval of gene therapy products in Europe and Asia and the upsurge of gene therapy products in clinical trials signal the rebound of this technology not only for many orphan diseases but also for non–life threatening diseases. Following the success of iPS cells in research, other modified *ex vivo* gene therapies are also knocking on the door of the clinic. Historically, gene therapy has experienced many ups and downs and still faces many challenges. During the past 10 years, many new ideas have been tried, and the goal of making this technology a more effective treatment modality through greater safety and control is coming within reach. The first clinical trial of iPS cells has begun, and cell mediated gene therapy products have reached phase III in some countries. The potential for tumorigenicity and immunogenicity are still concerns with these products, so physicians should understand the biological aspects of engineered cells in the clinic. In this review article, we attempted to provide a summary update of the current state of knowledge regarding this technology: that is, we reviewed products that have finished clinical trials, are still in clinical trials and/or are at the research stage. We also focused on the challenges, future directions, and strategies for making this technology available in the clinic. In addition, the available measures for making gene therapy products safer are within the scope of this article. It is also important to understand the manufacturing process for gene therapy products, because cell characteristics can change during the cell expansion process. When physicians use gene therapy products in the clinic, they should be aware of the viability, temperature sensitivity and stability of these cells because biologic products are different from chemical products. Although we may not be able to answer all possible questions and concerns, we believe that this is the right time for physicians to increase their interest in and understanding of this evolving technology.

**Key words:** Cell mediated gene therapy; Review; Physicians; Clinical and research stage; In the clinic

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this review article, the authors attempted to provide an up to date summary of the current knowledge regarding cell mediated gene therapy that is, we reviewed products that have finished clinical trial, are in clinical trial and at the research stage. The authors also tried to cover the challenges, future directions, and strategies to make this technology available in the clinic. This is the right time for the physicians to have knowledge of this evolving technology that already reached the bedside.

Noh MJ, Copeland O, O’Mara M, Lee KH. Cell mediated gene therapy: A guide for doctors in the clinic. *World J Med Genet* 2015; In press

**INTRODUCTION**

When the first gene therapy trial of hematopoietic cells and lymphocytes was reported[1], it seemed that gene therapy might be the answer to treating most orphan diseases without major complications. However, in early 2000, after the death of a patient during a gene therapy clinical trial[2,3], many researchers became very cautious about this new technology. The subsequent development of cancer as a result of *ex vivo* gene therapy treatment in 2003[4,5] made the regulatory authorities even more conservative. In 2009, after years of progress, the return of gene therapy was declared[6], and gene therapy was honored as “twenty-first century medicine”[7]. Three products hit the market: p53-expressing GendicineTM and AdvexinTM, conditionally replicating adenovirus OncorineTM and thymidine kinase + ganciclovir therapy, CereproTM[8]. In 2012, it was reported that over 1800 gene therapy clinical trials had been completed in 31 countries[9]. In addition, some countries’ governments have declared their intention to assist in the development of gene-related therapies at the federal government level.

More positive news for the field of gene therapy came with the award of the Nobel Prize for research on iPS cells in *ex vivo* gene therapy[10]. This technology has produced a seismic shift in stem cell research[11] and resulted in an increase in research for disease modeling of iPS cells[12]. The ultimate goal of these studies is the treatment of diseases that have not been treatable by conventional methods. Safety issues, manufacturing issues and product quality issues need to be addressed before these products become available in the clinic. Genetic engineering can make the cells more vulnerable to cancer development and therefore alternative engineering methods are needed[13]. To address these safety concerns, many papers have been published and several clinical trials have been performed to develop gene therapy technology for diseases in which there is no current available treatment.

Recently, the first clinical trial of iPS cells started in Japan[14], and *ex vivo* gene therapy for degenerative arthritis has reached phase III clinical trials[15]. In this review, we will discuss the status of cell mediated (*ex vivo*) gene therapy, including clinical trials, safety issues[16,17], and manufacturing issues for clinical applications[18,19]. In the clinic, physicians should understand the characteristics of the treatments that they are using. Cell-related products are new to most doctors, and their use presents a challenge because these treatments were not available during most doctors’ medical school education and resident training programs. In the area of regenerative medicine, these treatments cannot be confined to their own subspecialty. Understanding the mechanism of action of each product at the molecular level is necessary for doctors. We acknowledge that doctors can resist change, but we believe that understanding molecular medicine is similar to understanding new electronic technologies in everyday life.

**ENGINEERED CELLS FOR CLINICAL TRIAL AND RESEARCH**

The idea of multiple treatment modalities is familiar to physicians. For mesenchymal stem cell (MSC) differentiation, different combinations and effects of growth factors have been reported[20]. For gene therapy, the integration of multiple genes into cells (transfection) has been studied in many laboratories. The observation that cells into which multiple genes have been integrated show the characteristics of embryonic stem cells (ESCs) was first reported by the Yamanaka group in Japan[21]. This group inserted four factors, Oct3/4, Sox2, KLF4 and c-Myc, into fibroblasts, making them pluripotent. They showed that the engineered cells were similar to ESCs in terms of morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes and telomerase activity. Furthermore, these cells could differentiate into all of the cell types of the three germ layers *in vitro*. Other researchers showed the regenerative potential of iPS cells, with their ability to differentiate into various cell types[22-24]. To improve the safety of treatment with these cells, other researchers induced the differentiation of these cells without viral vectors[25,26] and even with recombinant proteins[27]. These strategies were reported to effectively eliminate any risk of modifying the target cell genome with exogenous genetic sequences. Consequently, the authors demonstrated the possibility of generating safer iPS cells. However, the stability of these cells has not been reported.

For clinical applications, the manufacturing process should produce batches of cells with the same characteristics. If the cells’ characteristics change in the presence of different concentrations of a protein, the manufacturing process is not validated for consistency. Safety analysis should also be performed prior to clinical trials. iPS cell-based therapies need to be thoroughly evaluated in pre-clinical animal models before they can be applied to human subjects[28,29]. Since 1998, the Food and Drug Administration (FDA) has been regulating cell therapies, beginning with “Guidance for human somatic cell therapy and gene therapy”. In 2008, the FDA released the guidelines “Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)”. In 2011, they released the guidelines “Potency tests for cellular and gene therapy products”. If cells are engineered to generate a product, the harvesting method (Good Tissue Practice), engineering method, and potency testing protocols should be clearly defined. From the beginning of the development process, the investigators should clearly understand the mechanism of action of the product to develop a manufacturing process with a method for harvesting cells and for testing them, to consistently produce well characterized, high-quality cell-based products. For example, Crook *et al*[30] (2007) reported on the activities and requirements for producing cGMP hESC lines including the derivation, banking, and characterization of these cells.

In 2014, Nature Medicine, in collaboration with the Volkswagen Foundation, organized a meeting with a panel of experts in regenerative medicine to identify the most pressing challenges, as well as to formulate the crucial strategies and stem cell concepts that could best help advance the field of translational regenerative medicine[31]. The panel identified four major issues: first, harnessing the potential of endogenous stem cells; second, deciphering therapeutic reprogramming; third, meeting the challenges of cell integration and function; and fourth, removing roadblocks to the translation of stem cell therapies. We believe that these opinions summarize the present and future of cell mediated gene therapy. Researchers have begun to address these challenges. In particular, one patient-specific pluripotent stem cell therapy has been reported to be safe with respect to immunogenicity and is nearing clinical trials[32]. Neurodegenerative disorders are very interesting clinical targets for this technology[33].

An enormous number of cell therapies have been tested worldwide for the treatment of rare diseases[34]. Regenerative medicine cannot be defined without MSCs and ESCs; however, gene therapy is also an important area in regenerative medicine. Many regenerative medicine companies have started up, and various umbrella organizations such as the Alliance for Regenerative Medicine have been formed. In 2009 and 2013, three very interesting studies were reported[35,36]. These studies integrated a lentiviral vector into patient hematopoietic stem cells and showed promising clinical results for Wiskott-Aldrich syndrome and X-linked adrenoleukodystrophy. In 2013, another group reported promising clinical results using lentiviral *ex vivo* gene therapy for metachromatic leukodystrophy[37]. These serial successes for rare diseases are a hallmark of this technology in the clinic. It is clear that this technology is the flag bearer for the future of treating rare diseases. It was a triumphant success to overcome the pessimistic environment that existed after leukemia developed in X-SCID patients treated with retroviral gene therapy[38]. In contrast to retroviral gene therapy, they extracted hematopoietic stem cells from a patient and transduced these cells with a lentiviral vector carrying specific genes (Wiskott-Aldrich gene, ABCD1 and ARSA), producing cell clones that did not carry integrations near oncogenes. Consistent with this, the authors did not observe evidence of clonal expansions in the patients for up to 20 to 32 mo after gene therapy treatment[35].

In 2007, induced pluripotent stem cell lines derived from human somatic cells were developed[39]. In 2008, it was reported that to better understand amyotrophic lateral sclerosis (ALS) and to develop a treatment, induced pluripotent stem cells were generated from a patient with the disease[23]. The authors generated iPS cells from an 82-year-old woman diagnosed with a familial form of ALS. These patient-specific iPS cells possessed properties of embryonic stem cells and were successfully directed to differentiate into motor neurons, the cell types destroyed in ALS. In 2009, an animal study of treating hemophilia A with iPS cells was reported[40]. The authors inserted the genes encoding 3 transcription factors, Oct4, Sox2 and Klf4, into somatic cells. The plasma FVIII levels in these mice increased to 8% to 12% of wild type, the hemophilia A phenotype was corrected. This study shows the possibility for future expansion of iPS cells into the clinic. Furthermore, Zhang *et al*[24] differentiated iPS cells into mature pancreatic insulin-producing cells. This work not only provides a new model with which to study the mechanism of human pancreatic specialization and maturation *in vitro* but also enables the possibility of utilizing patient-specific iPS cells for the treatment of diabetes[24].

Since the iPS cell researchers won the Nobel Prize, Japan has pioneered the clinical application of these cells in rare diseases. Previous success at treating degenerative disorders with gene therapy led researchers to pursue gene therapy for degenerative eye disorders[41,42]. In a proof-of-concept study, they showed that iPS cells developed a structured outer nuclear layer with complete inner and outer segments in 3D sheets. The authors also observed host-graft synaptic connections by immunohistochemistry. Eventually, they characterized and developed a human pluripotent stem cell-derived retinal pigment epithelium cell sheet for use in clinical trials. A clinical trial on macular degeneration is ongoing in Japan[43,44]. In their research on retinitis pigmentosa, the authors generated patient-derived iPS cells that recapitulated the disease phenotype and expressed markers of cellular stress. This research created the opportunity for understanding the disease by creating iPS cell models of degenerative disorders[45].

Recent trends in iPS cell research have allowed a shift to using iPS cells to model disease[46]. Degenerative disorders have been the main focus of this research. iPS cells use the same transcriptional network as ESCs to generate neuro-epithelia. iPS cells can be differentiated into functionally appropriate neuronal cell types over the same developmental time course as human ESCs in response to the same set of morphogens[47]. Therefore, researchers have suggested the possibility of employing human iPS cells in pathological studies, therapeutic screening and autologous cell transplantation[48]. Glial progenitor cells have also been suggested to be useful for modeling neurological diseases[49]. Chung *et al*[50] exploited the mutational correction of iPS cells and conserved the proteotoxic mechanisms to reverse the phenotypic response to α-synuclein, a key protein involved in Parkinson’s disease[50,51]. In 2014, iPS cell-based *in vitro* modeling of cardiomyopathy was also reported[52]. The authors combined patient-derived and genetically engineered iPS cells to elucidate the pathophysiology underlying the cardiomyopathy of Barth syndrome, a mitochondrial disorder caused by mutation of the gene encoding taffazzin (TAZ). Using Barth syndrome iPS-cell-derived cardiomyocytes, they defined metabolic, structural and functional abnormalities associated with TAZ mutation. Another interesting study reported modeling the genetic risk of schizophrenia by using iPS cells[12]. In addition, pathways that are disrupted in motor neurons in human ALS were also identified through the genetic correction of mutant SOD1[53]. The authors combined the reprogramming and differentiation of iPS cells with genome engineering and RNA sequencing to define the transcriptional and functional changes that are induced in human motor neurons by mutant SOD1[54,55].

Human pluripotent stem cells hold great potential for regenerative medicine, but the available cell types have limitations[56]. Recently, an international cell bank for iPS cells was created. In addition, Ma *et al*[57]’s approach of genome-wide analysis may be the future of iPS cell characterization. These authors examined the DNA methylation and transcriptome profiles of ESCs and somatic nuclear-transferred cells. They observed that the DNA methylation and transcriptome profiles of iPS cells retained residual DNA methylation patterns typical of parental somatic cells. Therefore, they concluded that human somatic cells can be accurately reprogrammed to pluripotency by somatic cell nuclear transfer and are therefore ideal for cell replacement therapy. This approach has opened an interesting field for the characterization of iPS cells in the future. A summary of selected clinical and preclinical research programs involving cell-mediated gene therapy is presented in Table 1.

**SAFETY AND EFFICACY ISSUES**

The fact that chondrocytes can be induced to differentiate into fibroblasts during cell culture spurs questions about potential differentiation issues. The continuation of the cell division process relies on the interaction of the cells with a microenvironment that consists of other cells and the extracellular matrix[58]. Cells respond to a variety of growth factors. The autocrine and paracrine modes of cell stimulation are key elements in this process. The differentiation of murine C3H10T1/2 mesenchymal cells into chondrocytes in response to bone morphogenic protein has been observed[59]. Similar papers have reported on the differentiation of specific cells into cells with different characteristics[60]. Dedifferentiation-associated changes in morphology and gene expression have also been reported in primary human chondrocytes in culture[61]. These observations make the TGF-β superfamily proteins possible target modifiers of cartilage and bone formation. However, there is also a concern with regard to safety and efficacy because changes in other characteristics can change the properties of a cell therapy and therefore make the cells unacceptable as a treatment. With respect to efficacy, these findings brought forth the need to identify clear biomarkers to identify and characterize cells for potential transplantation.

Some researchers previously thought that MSCs do not induce immunogenicity. A report showing that human stem cells modulate the allogeneic immune response made people change their view about this concept[62]. In 2005, several papers were published relating to the immunogenicity of mesenchymal stem cells. At this time, there was some confusion regarding the immunogenicity of mesenchymal stem cells. The T cell response to allogeneic human MSCs was evaluated for immunogenicity, tolerance and suppression[63]. The authors concluded that MSCs can initiate the activation of T cells but do not elicit a T cell proliferative response because of an active suppression mechanism. These data were in support of Aggarwat and Pittenger’s work that was previously cited. However, somewhat contradictory data were also reported[64,65], namely that MSC immunogenicity was increased upon differentiation after transplantation into human and murine ischemic myocardium. This paper indicated that differentiation of cells after injection into organs can cause problems, and the authors recommended a requirement for immunosuppressive therapy. They also indicated that allogeneic MSCs are not intrinsically immune privileged and that allogeneic MSCs can induce a T-cell response under appropriate conditions. In a pig study, intracardiac allogeneic porcine MSCs elicited an immune response despite their low immunogenic profile *in vitro*[66]. This suggests that the *in vivo* characteristics of allogeneic MSCs might differ and emphasizes the importance of pursuing research both *in vitro* and *in vivo*. More specifically, allogeneic MSCs have been shown to induce immunogenicity, which limited their long term benefits for myocardial repair[22]. The authors of this study concluded that the long-term ability of allogeneic MSCs to preserve function in the infarcted heart is limited by a biphasic immune response whereby these cells transit from an immune privileged state to an immunogenic state after differentiation. We believe that not only the cell type but also the injection site is an important factor for immunogenicity.

To determine the potential for the biodistribution of gene-modified cells, the FDA recommends intravenous administration in an animal study to assess systemic distribution and persistence of the cells. Transduced genes can be the target for determining the distribution in cell-mediated gene therapy. After a single intravenous administration, the major organs should be checked to review the clearance of the cells for at least 30 d and for up to three months after injection. At this stage of preclinical development, the maximum tolerated dose should be calculable[67]. For safety and efficacy tests in animals, it is the standard practice to perform testing in two animal species. Clinical and histological analyses are included among the safety and efficacy tests, and treatment-related and dose-related toxicities can be assessed.

Single and multiple dose toxicity testing with up to a 1 year follow-up period may be required depending on the nature of the disease and the mode of treatment. The no-observed-adverse-effect level can be evaluated with these studies[68]. This can be defined as the highest experimental point that is without adverse effects, although it does not address risk based on toxicologically relevant effects nor does it consider the progression of effects with respect to the duration or dose. In characterizing cell lines, the FDA may request tumorigenicity testing in accordance with the “Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals” guidelines. Further studies of gene-modified cells may be recommended to assess the potential for these cells to adversely differentiate for 6 wk or up to 6 mo. Additional studies can be requested depending on the characteristics of the treatment modality. For allogeneic cells, studies to determine immunogenicity are required and may include assessing the HLA antigen expression by the cells, anti-HLA antibodies, the T cell response and multiple cytokines in animals and/or humans.

**TUMORIGENICITY**

Karyotype analysis by using chromosome banding is the standard method for identifying numerical and structural chromosomal aberrations. A novel karyotyping technique, termed spectral karyotyping, was developed to increase the sensitivity of karyotyping[69]. After reports of problems with viral vectors in gene therapy[70,71], this karyotyping issue becomes important in the cell-mediated gene therapy field. The FDA had concerns regarding injecting cells with chromosomal abnormalities in human clinical trials[72,73]. This concern arose as a result of the leukemia observed in the clinical trial of X-SCID patients. Oncogenesis or tumorigenicity has been considered a clinical hurdle for pluripotent stem cell therapies by certain authors[74,75]. These authors identified the seven risks of iPS cell therapy: integration of the gene into the host cell, chromosomal damage, clonal selection, incomplete programming, failure to silence pluripotent networks, DNA damage during cell culture and aberrant regulation of the imprinting process[76]. Adeno-associated virus was considered a relatively safe vector, but several authors still consider that this vector can induce chromosomal abnormalities[77,78]. For cells in which there is a karyotyping change after transfection[79], the FDA recommends rendering the cells replication incompetent (*e.g.*, *via* irradiation) prior to their being used in a clinical setting.

In 2003, one of the most successful, problematic and influential cases of gene therapy was reported: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1[4,80]. The authors previously showed the correction of X-linked severe combined immunodeficiency in 9 out of 10 patients by using retrovirus-mediated gene transfer to autologous CD34+ bone marrow cells. However, 3 years after this gene therapy, uncontrolled, exponential clonal proliferation of mature T cells occurred in two patients. This incident was reported as an occurrence of leukemia following gene therapy[81]. Although these patients overcame the problem, the impact of this incident was sufficient to change the arena in terms of regulation, investment and research effort. Baum *et al*[38] (2003) reviewed the side effects of this technology that are related to target cell manipulation, vector production, transgene insertion and expression, selection procedures for transgenic cells and immune surveillance. This unfortunate leukemic side effect of gene therapy can be used as a learning tool for developing safer, more effective gene therapies in the future.

To overcome these potential side effects of gene therapy, many possible solutions have been devised[17,82]. Chromosomal insulators, co-transfection of suicide genes under control of an inducible promoter, conditional expression of the transgene only in appropriate target cells, targeted transduction, cell type specific expression, targeted local administration, splitting of the viral genome, and site-specific insertion of the retroviral vector have all been proposed. A global iPS cell library has been proposed to preselect the donor genotype for immunological matching. This approach was proposed for immune compatibility[83], and similar approaches to reducing the potential for tumorigenicity can be devised. Individual cell lines that have undergone insertion site[84] and gene expression analyses and have otherwise been evaluated for tumorigenicity and determined to be non-tumorigenic can be identified and used for other clinical trials. To reach this goal, more clinical and *in vitro* and *in vivo* non-clinical data should be generated.

**MECHANISM OF ACTION AND BIOMARKER**

Some mesenchymal stem cell populations are relatively easy to harvest: for example, bone marrow MSCs. However, clinical application of these cells without preclinical evidence of efficacy and safety is unacceptable and will delay the development of clinically useful therapies[16]. In particular, we need to better understand the mechanisms of action of stem cells after transplantation and learn how to control stem cell proliferation, survival, migration, and differentiation in pathological environments[33]. Stem cell-based approaches have received much hype as potential treatments for neurodegenerative disorders. Indeed, they showed that transplantation of stem cells in an animal model of neurodegenerative disease can improve function by replacing lost neurons and glial cells and by mediating remyelination, trophic actions and modulation of inflammation. However, a clear understanding of the mechanism of action and a description of a biomarker for demonstrating efficacy should be devised for use in clinical trials.

Proposals submitted to the FDA for MSC-based products are undergoing a rapid expansion and are characterized by increased variability in donor and tissue sources, manufacturing processes, proposed functional mechanisms and characterization methods[85]. Mendicino *et al*[85] attempted to elucidate the FDA’s current perspective on the characterization of MSC-based products for clinical trials. The FDA proposed to characterize cell surface markers for IND applications of MSC-based products. Additionally, they found significant heterogeneity in the description of MSC bioactivity characterization in situations in which a candidate marker for a given assay has been defined. It remains unclear which particular set of markers will be sufficient to describe this complex and heterogeneous product class. Markers that can predict potential therapeutic benefit may allow the correlation of MSC characterization data with clinical data as they become available. For iPS cells, it can be more complicated.

iPS cells have been enthusiastically presented as a tool for aiding drug discovery by drug discoverers and commercial reagent and service providers alike[86]. The future trend for research in this area relates to the maintenance of pluripotency and cellular reprogramming[87]. To bring a product to the clinic, licensing, intellectual property and legal issues are also important. At this time, there may not be enough information for financial and business development professionals to evaluate the marketability of these products. Issues with developing cellular products and related assay development are only some of the challenges that are faced when integrating iPS cells into drug discovery. However, the potential for these cells to markedly improve the symptoms of patients motivates those involved in drug discovery to invest time and money to advance this technology.

**MANUFACTURING OF CELL PRODUCTS**

One of the hurdles limiting the development of cellular therapies is the difficulty of cell expansion and the mass production required for a commercial product. The manufacturing technology for these products has developed in parallel with research on these products. Since the initial reports of the use of disposable bioreactors for cell culture that use wave-induced agitation[88,89], many innovations in single-use bioreactors have been reported[90]. The technology ranges from 175 cm2 tissue culture flasks to methods for scalable expansion of the cells[91]. Routine commercial and clinical applications of human cells and their progeny require increasing cell quantities that cannot be provided by conventional adherent culture techniques. Straightforward protocols for the expansion of undifferentiated ESC and iPS cells in suspension culture have been developed and reported. For ESCs, different methods for expansion to improve the culture conditions have been evaluated[92]. A scalable GMP-compliant suspension system for human ESCs was reported by Chen *et al*[18,93]. This suspension culture system provides a powerful approach for scaling-up the expansion of hESCs under defined, serum-free conditions for clinical and research applications[94].

Disposable bioreactors are already widely accepted and in use for protein manufacturing[92,95]. Disposable components and systems are increasingly favored, both for improved process reliability and for the economic advantage they offer. For this reason, many biotech producers of protein molecules are moving to disposable bioreactor modules that are pre-sterilized and meet the applicable regulatory requirements. In 2010, Eibl *et al*[96] published a paper regarding disposable bioreactors, including the current state-of-the-art and recommended applications in biotechnology[96]. In their paper, they provided a summary overview of the disposable bioreactors that were commercially available and described the domination of wave-mixed, orbitally shaken and stirred disposable bench top systems. They concluded that these novel systems are a viable alternative to traditional cell culture bioreactors at the bench top scale.

In 1997, Genzyme gained approval for autologous chondrocyte transplantation. Although this technology was not a commercial success, it fueled the development of mass culture methods for chondrocytes. Not only have chondrocytes been used for the regeneration of cartilage in the knee of patients[97], but they have also been used for intervertebral disc regeneration[98]. To expand these cells for commercial usage, chondrocytes have been cultured and expanded in a microcarrier system[60,99,100]. They investigated human chondrocyte expansion in four macroporous gelatin microcarriers using two manufacturing processes that differed with respect to the amount of emulsifier used during the initial preparation and the gelatin cross-linking medium. The authors observed a strong chondrocyte donor effect during the initial expansion phase. The final cell yield differed significantly between the microcarriers, and the result indicated that manufacturing differences affected chondrocyte densities.

For iPS cells, large-scale culture relies on the combined use of multiple growth components, including media containing various growth factors, extracellular matrices, 3D environmental cues and modes of multicellular association[18]. Chen *et al*[18] describe the criteria, considerations and suggestions for achieving optimal iPS cell growth.

**RELEASE TEST AND QUALITY CONTROL**

As for chemical drugs, biological drugs should be consistent, active, pure, toxin-free and stable. Growth, harvesting and distribution into vials of cells should be conducted in a controlled GMP environment (Table 2). Throughout the manufacturing process, in-process and release testing should be performed to ensure that each batch of product is safe and consistently meets the criteria for identity, purity and potency prior to administration to humans. The characteristics, viability and potency of the cells should be evaluated. The identity of the cells can be defined by morphologic examination and by markers of specific functions. For example, Type II collagen and GAG production are relevant criteria for cartilage cells. Techniques such as immunohistochemical staining and RT-PCR are also good tools for this purpose. Cell potency can be measured by a quantitative analysis such as ELISA for specific therapeutic protein production, or by other product specific assays depending on the therapeutic mechanism. Cell viability and proliferation can be determined by specific staining (*e.g.*, tryptophan blue), MTT assay and/or by automated methods using fluoroscopy. For gene-modified cells generated with a viral vector, replication-competent retrovirus detection may be required as a safety evaluation (Table 3).

The cells should also be tested for contamination by checking sterility, detecting mycoplasma and measuring endotoxin levels. The long-term stability of cells should also be determined under the conditions of storage, use and shipping. This may require testing under different conditions such as room temperature, refrigeration, and frozen (at temperature ranges corresponding to dry ice and the vapor phase of liquid nitrogen storage).

**IN THE CLINIC**

One of the first routes of delivery of cellular therapy was intra-articular because of some inherent advantages[101,102]. Some of the benefits of local delivery over systemic delivery include increased bioavailability, fewer adverse events, and lower total drug costs. Additionally, the intra-articular injection of cell therapies has advantages over intravenous administration in that systemic exposure is reduced and exposure to the antigen surveillance system is limited[103]. For these reasons, we have developed a cell mediated gene therapy for degenerative joint disease[104-106] and are currently conducting clinical trials with normal and engineered chondrocytes (called TG-C) injected into the knee joint for the treatment of osteoarthritis (Figure 1).

We are currently completing a Phase II study entitled ‘A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-β1 in Patients with Grade 3 Chronic Degenerative Joint Disease of the Knee’ in the United States. Phase III testing of this product is currently ongoing in South Korea. To develop this product for clinical use, it was necessary to establish the stability of the product under frozen storage conditions and at room temperature for injection. The temperature of the product as it was transferred from manufacturing to storage to the clinic and within the clinic was carefully controlled and monitored. To date, more than 220 patients have been injected with TG-C. A schematic diagram of the manufacturing and injection processes is presented in Figure 1. The gene-modified cells in TG-C are irradiated to render them replication incompetent. These cells therefore produce the active TGF-β protein for only two weeks. These irradiated cells also produce Type-II collagen and glycosaminoglycan (GAG) by an autocrine mode of action and induce normal chondrocytes to produce Type II collagen and GAG by a paracrine mode of action in response to the TGF-β protein produced. The releasing tests during the manufacturing of TG-C are described in Table 4.

As TG-C is an allogeneic product; all patients in this study are being monitored for an immune response. To date, no immune response or serious adverse events attributable to TG-C have been observed. The decreased HLA-type antigenicity of the cells and the relatively immune privileged nature of the intra-articular injection site are thought to be contributing factors to the lack of immune response.

**CONCLUDING REMARKS**

Our understanding of the nature of cell-based products and the diseases that they are intended to treat is being increased empirically: that is, through the scientific process of trial and error. Human clinical trials with cutting edge technology and novel products are part of that process and accordingly have their failures and successes, which are necessary if we are to learn and improve our understanding. Industry’s perspective of cell-based therapy has changed in response to scientific developments and discoveries[41]. Although there is a long way to go, a tremendous amount of clinical data have already been generated. In this review, we summarized the ongoing scientific effort to move cell mediated gene therapy into the clinic. While some may still believe that such therapy is far from the clinic, it is our belief that now is the time for physicians to understand and embrace this new technology.

**REFERENCES**

1 **Anderson WF**. Gene therapy. The best of times, the worst of times. *Science* 2000; **288**: 627-629 [PMID: 10799000 DOI: 10.1126/science.288.5466.627]

2 **Marshall E**. Gene therapy death prompts review of adenovirus vector. *Science* 1999; **286**: 2244-2245 [PMID: 10636774]

3 **Savulescu J**. Harm, ethics committees and the gene therapy death. *J Med Ethics* 2001; **27**: 148-150 [PMID: 11417019 DOI: 10.1136/jme.27.3.148]

4 **Hacein-Bey-Abina S**, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 2003; **302**: 415-419 [PMID: 14564000 DOI: 10.1126/science.1088547]

5 **Hacein-Bey-Abina S**, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med* 2003; **348**: 255-256 [PMID: 12529469 DOI: 10.1056/NEJM200301163480314]

6 **Naldini L**. Medicine. A comeback for gene therapy. *Science* 2009; **326**: 805-806 [PMID: 19892968 DOI: 10.1126/science.1181937]

7 **Verma IM**, Weitzman MD. Gene therapy: twenty-first century medicine. *Annu Rev Biochem* 2005; **74**: 711-738 [PMID: 15952901 DOI: 10.1146/annurev.biochem.74.050304.091637]

8 **Räty JK**, Pikkarainen JT, Wirth T, Ylä-Herttuala S. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. *Curr Mol Pharmacol* 2008; **1**: 13-23 [PMID: 20021420 DOI: 10.2174/1874467210801010013]

9 **Ginn SL**, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. *J Gene Med* 2013; **15**: 65-77 [PMID: 23355455 DOI: 10.1002/jgm.2698]

10 **Takahashi K**, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861-872 [PMID: 18035408 DOI: 10.1016/j.cell.2007.11.019]

11 **Holden C**, Vogel G. Cell biology. A seismic shift for stem cell research. *Science* 2008; **319**: 560-563 [PMID: 18239100 DOI: 10.1126/science.319.5863.560]

12 **Yoon KJ**, Nguyen HN, Ursini G, Zhang F, Kim NS, Wen Z, Makri G, Nauen D, Shin JH, Park Y, Chung R, Pekle E, Zhang C, Towe M, Hussaini SM, Lee Y, Rujescu D, St Clair D, Kleinman JE, Hyde TM, Krauss G, Christian KM, Rapoport JL, Weinberger DR, Song H, Ming GL. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. *Cell Stem Cell* 2014; **15**: 79-91 [PMID: 24996170 DOI: 10.1016/j.stem.2014.05.003]

13 **Doulatov S**, Daley GQ. Development. A stem cell perspective on cellular engineering. *Science* 2013; **342**: 700-702 [PMID: 24202165 DOI: 10.1126/science.1238363]

14 **Kamao H**, Mandai M, Okamoto S, Sakai N, Suga A, Sugita S, Kiryu J, Takahashi M. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. *Stem Cell Reports* 2014; **2**: 205-218 [PMID: 24527394 DOI: 10.1016/j.stemcr.2013.12.007]

15 **Ha CW**, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. *Cytotherapy* 2012; **14**: 247-256 [PMID: 22242865 DOI: 10.3109/14653249.2011.629645]

16 **Daley GQ**. The promise and perils of stem cell therapeutics. *Cell Stem Cell* 2012; **10**: 740-749 [PMID: 22704514 DOI: 10.1016/j.stem.2012.05.010]

17 **Yi Y**, Hahm SH, Lee KH. Retroviral gene therapy: safety issues and possible solutions. *Curr Gene Ther* 2005; **5**: 25-35 [PMID: 15638709 DOI: 10.2174/1566523052997514]

18 **Chen VC**, Couture SM, Ye J, Lin Z, Hua G, Huang HI, Wu J, Hsu D, Carpenter MK, Couture LA. Scalable GMP compliant suspension culture system for human ES cells. *Stem Cell Res* 2012; **8**: 388-402 [PMID: 22459095 DOI: 10.1016/j.scr.2012.02.001]

19 **Moon SY**, Park YB, Kim DS, Oh SK, Kim DW. Generation, culture, and differentiation of human embryonic stem cells for therapeutic applications. *Mol Ther* 2006; **13**: 5-14 [PMID: 16242999 DOI: 10.1016/j.ymthe.2005.09.008]

20 **Kratchmarova I**, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. *Science* 2005; **308**: 1472-1477 [PMID: 15933201 DOI: 10.1126/science.1107627]

21 **Takahashi K**, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006; **126**: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]

22 **Ieda M**, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell* 2010; **142**: 375-386 [PMID: 20691899 DOI: 10.1016/j.cell.2010.07.002]

23 **Pajcini KV**, Corbel SY, Sage J, Pomerantz JH, Blau HM. Transient inactivation of Rb and ARF yields regenerative cells from postmitotic mammalian muscle. *Cell Stem Cell* 2010; **7**: 198-213 [PMID: 20682446 DOI: 10.1016/j.stem.2010.05.022]

24 **Zhang D**, Jiang W, Liu M, Sui X, Yin X, Chen S, Shi Y, Deng H. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. *Cell Res* 2009; **19**: 429-438 [PMID: 19255591 DOI: 10.1038/cr.2009.28]

25 **Okita K**, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. *Science* 2008; **322**: 949-953 [PMID: 18845712 DOI: 10.1126/science.1164270]

26 **Stadtfeld M**, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. *Science* 2008; **322**: 945-949 [PMID: 18818365]

27 **Zhou H**, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Schöler HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 2009; **4**: 381-384 [PMID: 19398399 DOI: 10.1016/j.stem.2009.04.005]

28 **Sun N**, Longaker MT, Wu JC. Human iPS cell-based therapy: considerations before clinical applications. *Cell Cycle* 2010; **9**: 880-885 [PMID: 20160515 DOI: 10.4161/cc.9.5.10827]

29 **Yamanaka S**. A fresh look at iPS cells. *Cell* 2009; **137**: 13-17 [PMID: 19345179 DOI: 10.1016/j.cell.2009.03.034]

30 **Crook JM**, Peura TT, Kravets L, Bosman AG, Buzzard JJ, Horne R, Hentze H, Dunn NR, Zweigerdt R, Chua F, Upshall A, Colman A. The generation of six clinical-grade human embryonic stem cell lines. *Cell Stem Cell* 2007; **1**: 490-494 [PMID: 18938745 DOI: 10.1016/j.stem.2007.10.004]

31 **Dimmeler S**, Ding S, Rando TA, Trounson A. Translational strategies and challenges in regenerative medicine. *Nat Med* 2014; **20**: 814-821 [PMID: 25100527 DOI: 10.1038/nm.3627]

32 **Kiskinis E**, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. *J Clin Invest* 2010; **120**: 51-59 [PMID: 20051636 DOI: 10.1172/JCI40553]

33 **Lindvall O**, Kokaia Z. Stem cells in human neurodegenerative disorders--time for clinical translation? *J Clin Invest* 2010; **120**: 29-40 [PMID: 20051634 DOI: 10.1172/JCI40543]

34 **Cristante AF**, Barros-Filho TE, Tatsui N, Mendrone A, Caldas JG, Camargo A, Alexandre A, Teixeira WG, Oliveira RP, Marcon RM. Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients. *Spinal Cord* 2009; **47**: 733-738 [PMID: 19333245 DOI: 10.1038/sc.2009.24]

35 **Aiuti A**, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee PP, Orange JS, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science* 2013; **341**: 1233151 [PMID: 23845947 DOI: 10.1126/science.1233151]

36 **Cartier N**, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrère F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougnères P, Von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* 2009; **326**: 818-823 [PMID: 19892975 DOI: 10.1126/science.1171242]

37 **Biffi A**, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. *Science* 2013; **341**: 1233158 [PMID: 23845948 DOI: 10.1126/science.1233158]

38 **Baum C**, Düllmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. *Blood* 2003; **101**: 2099-2114 [PMID: 12511419 DOI: 10.1182/blood-2002-07-2314]

39 **Yu J**, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007; **318**: 1917-1920 [PMID: 18029452 DOI: 10.1126/science.1151526]

40 **Xu D**, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. *Proc Natl Acad Sci U S A* 2009; **106**: 808-813 [PMID: 19139414 DOI: 10.1073/pnas.0812090106]

41 **Assawachananont J**, Mandai M, Okamoto S, Yamada C, Eiraku M, Yonemura S, Sasai Y, Takahashi M. Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. *Stem Cell Reports* 2014; **2**: 662-674 [PMID: 24936453 DOI: 10.1016/j.stemcr.2014.03.011]

42 **Jin ZB**, Okamoto S, Osakada F, Homma K, Assawachananont J, Hirami Y, Iwata T, Takahashi M. Modeling retinal degeneration using patient-specific induced pluripotent stem cells. *PLoS One* 2011; **6**: e17084 [PMID: 21347327 DOI: 10.1371/journal.pone.0017084]

43 **Cyranoski D**. Japan's stimulus package showers science with cash. *Nature* 2013; **493**: 465 [PMID: 23344339 DOI: 10.1038/493465a]

44 **Cyranoski D**. Stem cells cruise to clinic. *Nature* 2013; **494**: 413 [PMID: 23446394 DOI: 10.1038/494413a]

45 **Durak O**, Tsai LH. Human induced pluripotent stem cells: now open to discovery. *Cell Stem Cell* 2014; **15**: 4-6 [PMID: 24996162 DOI: 10.1016/j.stem.2014.06.014]

46 **Israel MA**, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* 2012; **482**: 216-220 [PMID: 22278060 DOI: 10.1038/nature10821]

47 **Hu BY**, Weick JP, Yu J, Ma LX, Zhang XQ, Thomson JA, Zhang SC. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. *Proc Natl Acad Sci U S A* 2010; **107**: 4335-4340 [PMID: 20160098 DOI: 10.1073/pnas.01910012107]

48 **Merkle FT**, Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. *Cell Stem Cell* 2013; **12**: 656-668 [PMID: 23746975 DOI: 10.1016/j.stem.2013.05.016]

49 **Goldman SA**, Nedergaard M, Windrem MS. Glial progenitor cell-based treatment and modeling of neurological disease. *Science* 2012; **338**: 491-495 [PMID: 23112326 DOI: 10.1126/science.1218071]

50 **Chung CY**, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Schüle B, Lippard SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist S. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. *Science* 2013; **342**: 983-987 [PMID: 24158904 DOI: 10.1126/science.1245296]

51 **Seibler P**, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. *J Neurosci* 2011; **31**: 5970-5976 [PMID: 21508222 DOI: 10.1523/JNEUROSCI.4441-10.2011]

52 **Wang G**, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, Pu WT. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. *Nat Med* 2014; **20**: 616-623 [PMID: 24813252 DOI: 10.1038/nm.3545]

53 **Kiskinis E**, Sandoe J, Williams LA, Boulting GL, Moccia R, Wainger BJ, Han S, Peng T, Thams S, Mikkilineni S, Mellin C, Merkle FT, Davis-Dusenbery BN, Ziller M, Oakley D, Ichida J, Di Costanzo S, Atwater N, Maeder ML, Goodwin MJ, Nemesh J, Handsaker RE, Paull D, Noggle S, McCarroll SA, Joung JK, Woolf CJ, Brown RH, Eggan K. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. *Cell Stem Cell* 2014; **14**: 781-795 [PMID: 24704492 DOI: 10.1016/j.stem.2014.03.004]

54 **Chen H**, Qian K, Du Z, Cao J, Petersen A, Liu H, Blackbourn LW, Huang CL, Errigo A, Yin Y, Lu J, Ayala M, Zhang SC. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. *Cell Stem Cell* 2014; **14**: 796-809 [PMID: 24704493 DOI: 10.1016/j.stem.2014.02.004]

55 **Dimos JT**, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 2008; **321**: 1218-1221 [PMID: 18669821 DOI: 10.1126/science.1158799]

56 **Fox IJ**, Daley GQ, Goldman SA, Huard J, Kamp TJ, Trucco M. Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. *Science* 2014; **345**: 1247391 [PMID: 25146295 DOI: 10.1126/science.1247391]

57 **Ma H**, Morey R, O'Neil RC, He Y, Daughtry B, Schultz MD, Hariharan M, Nery JR, Castanon R, Sabatini K, Thiagarajan RD, Tachibana M, Kang E, Tippner-Hedges R, Ahmed R, Gutierrez NM, Van Dyken C, Polat A, Sugawara A, Sparman M, Gokhale S, Amato P, Wolf DP, Ecker JR, Laurent LC, Mitalipov S. Abnormalities in human pluripotent cells due to reprogramming mechanisms. *Nature* 2014; **511**: 177-183 [PMID: 25008523 DOI: 10.1038/nature13551]

58 **Cancedda R**, Descalzi Cancedda F, Castagnola P. Chondrocyte differentiation. *Int Rev Cytol* 1995; **159**: 265-358 [PMID: 7737795 DOI: 10.1016/S0074-7696(08)62109-9]

59 **Denker AE**, Haas AR, Nicoll SB, Tuan RS. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures. *Differentiation* 1999; **64**: 67-76 [PMID: 10234804 DOI: 10.1046/j.1432-0436.1999.6420067.x]

60 **Frondoza C**, Sohrabi A, Hungerford D. Human chondrocytes proliferate and produce matrix components in microcarrier suspension culture. *Biomaterials* 1996; **17**: 879-888 [PMID: 8718933 DOI: 10.1016/0142-9612(96)83283-2]

61 **Schnabel M**, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vécsei V, Schlegel J. Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. *Osteoarthritis Cartilage* 2002; **10**: 62-70 [PMID: 11795984 DOI: 10.1053/joca.2001.0482]

62 **Aggarwal S**, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; **105**: 1815-1822 [PMID: 15494428 DOI: 10.1182/blood-2004-04-1559]

63 **Klyushnenkova E**, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. *J Biomed Sci* 2005; **12**: 47-57 [PMID: 15864738 DOI: 10.1007/s11373-004-8183-7]

64 **Nauta AJ**, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. *Blood* 2006; **108**: 2114-2120 [PMID: 16690970 DOI: 10.1182/blood-2005-11-011650]

65 **Swijnenburg RJ**, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F, Lebl DR, Caffarelli AD, de Bruin JL, Fedoseyeva EV, Robbins RC. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. *Circulation* 2005; **112**: I166-I172 [PMID: 16159810 DOI: 10.1161/CIRCULATIONAHA.104.525824]

66 **Poncelet AJ**, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. *Transplantation* 2007; **83**: 783-790 [PMID: 17414713 DOI: 10.1097/01.tp.0000258649]

67 **Gaylor DW**, Gold LS. Quick estimate of the regulatory virtually safe dose based on the maximum tolerated dose for rodent bioassays. *Regul Toxicol Pharmacol* 1995; **22**: 57-63 [PMID: 7494904 DOI: 10.1006/rtph.1995.1069]

68 **Dorato MA**, Engelhardt JA. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). *Regul Toxicol Pharmacol* 2005; **42**: 265-274 [PMID: 15979222 DOI: 10.1016/j.yrtph.2005.05.004]

69 **Schröck E**, Veldman T, Padilla-Nash H, Ning Y, Spurbeck J, Jalal S, Shaffer LG, Papenhausen P, Kozma C, Phelan MC, Kjeldsen E, Schonberg SA, O'Brien P, Biesecker L, du Manoir S, Ried T. Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. *Hum Genet* 1997; **101**: 255-262 [PMID: 9439652 DOI: 10.1007/s004390050626]

70 **Cavazzana-Calvo M**, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science* 2000; **288**: 669-672 [PMID: 10784449 DOI: 10.1126/science.288.5466.669]

71 **Thomas CE**, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. *Nat Rev Genet* 2003; **4**: 346-358 [PMID: 12728277 DOI: 10.1038/nrg1066]

72 **US department of health and human service, FDA.** CIBER: Guide for industry: Content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications(IND), 2008. Available from: URL:http: //www.fda.gov/cber/guidelines.htm

73 **US department of health and human service, FDA**. CIBER: Guide for industry: Potency tests for cellular and gene therapy products, 2011. Available from: URL: http: //www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatory Information/Guidances/default.htm

74 **Ismail SI**, Kingsman SM, Kingsman AJ, Uden M. Split-intron retroviral vectors: enhanced expression with improved safety. *J Virol* 2000; **74**: 2365-2371 [PMID: 10666267 DOI: 10.1128/JVI.74.5.2365-2371.2000]

75 **Lee AS**, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. *Nat Med* 2013; **19**: 998-1004 [PMID: 23921754 DOI: 10.1038/nm.3267]

76 **Emery DW**, Yannaki E, Tubb J, Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. *Proc Natl Acad Sci U S A* 2000; **97**: 9150-9155 [PMID: 10908661 DOI: 10.1073/pnas.160159597]

77 **Connolly JB**. Lentiviruses in gene therapy clinical research. *Gene Ther* 2002; **9**: 1730-1734 [PMID: 12457288 DOI: 10.1038/sj.gt.3301893]

78 **Frederickson RM**. Integrating ideas on insertional mutagenesis by gene transfer vectors. *Mol Ther* 2007; **15**: 1228-1232 [PMID: 17579594 DOI: 10.1038/sj.mt.6300234]

79 **Friedmann T**. Gene therapy's new era: a balance of unequivocal benefit and unequivocal harm. *Mol Ther* 2003; **8**: 5-7 [PMID: 12872762 DOI: 10.1016/S1525-0016(03)00190-4]

80 **Kaiser J**. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. *Science* 2003; **299**: 495 [PMID: 12543948 DOI: 10.1126/science.299.5606.495]

81 **Kohn DB**, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. *Nat Rev Cancer* 2003; **3**: 477-488 [PMID: 12835668 DOI: 10.1038/nrc1122]

82 **Yi Y**, Noh MJ, Lee KH. Current advances in retroviral gene therapy. *Curr Gene Ther* 2011; **11**: 218-228 [PMID: 21453283 DOI: 10.2174/156652311795684740]

83 **Turner M**, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A, Turner D, Yamanaka S, Wilmut I. Toward the development of a global induced pluripotent stem cell library. *Cell Stem Cell* 2013; **13**: 382-384 [PMID: 24094319 DOI: 10.1016/j.stem.2016.08.003]

84 **Veres A**, Gosis BS, Ding Q, Collins R, Ragavendran A, Brand H, Erdin S, Cowan CA, Talkowski ME, Musunuru K. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. *Cell Stem Cell* 2014; **15**: 27-30 [PMID: 24996167 DOI: 10.1016/j.stem.2014.04.020]

85 **Mendicino M**, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. *Cell Stem Cell* 2014; **14**: 141-145 [PMID: 24506881 DOI: 10.1016/j.stem.2014.01.013]

86 **Engle SJ**, Puppala D. Integrating human pluripotent stem cells into drug development. *Cell Stem Cell* 2013; **12**: 669-677 [PMID: 23746976 DOI: 10.1016/j.stem.2013.05.011]

87 **Gonzalez-Muñoz E**, Arboleda-Estudillo Y, Otu HH, Cibelli JB. Cell reprogramming. Histone chaperone ASF1A is required for maintenance of pluripotency and cellular reprogramming. *Science* 2014; **345**: 822-825 [PMID: 25035411 DOI: 10.1126/science.1254745]

88 **De Jesus MJ**, Girard P, Bourgeois M, Baumgartner G, Kacko B, Amstutz H and Wurm FM. TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology. *Biochem Eng J* 2004; **17:** 217-223 [DOI: 10.1016/S1369-703X(03)00180-3]

89 **Singh V**. Disposable bioreactor for cell culture using wave-induced agitation. *Cytotechnology* 1999; **30**: 149-158 [PMID: 19003364 DOI: 10.1023/A: 1008025016272]

90 **Siddiquee K**, Ma S. Large-scale production of human mesenchymal stem cells in BioBLU 5c Single-use vessels. *Application Note* 2014; **334**: 1-10

91 **Zweigerdt R**, Olmer R, Singh H, Haverich A, Martin U. Scalable expansion of human pluripotent stem cells in suspension culture. *Nat Protoc* 2011; **6**: 689-700 [PMID: 21527925 DOI: 10.1038/nprot.2011.318]

92 **Morrow KJ**. Disposable bioreactors gaining favor: New components and systems improve process reliability and reduce cost. *Genetic Engineering News* 2006: 26-12, 42-45

93 **Chen KG**, Mallon BS, McKay RD, Robey PG. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. *Cell Stem Cell* 2014; **14**: 13-26 [PMID: 24388173 DOI: 10.1016/j.stem.2013.12.005]

94 **Genzel Y**, Olmer RM, Schäfer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. *Vaccine* 2006; **24**: 6074-6087 [PMID: 16781022 DOI: 10.1016/j.vaccine.2006.05.023]

95 **Hami LS**, Chana H, Yuan V and Craig S: Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. *Bio Processing J* 2003; 2: 1-10

96 **Eibl R**, Kaiser S, Lombriser R, Eibl D. Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. *Appl Microbiol Biotechnol* 2010; **86**: 41-49 [PMID: 20094714 DOI: 10.1007/s00253-009-2422-9]

97 **Cole BJ,** D’Amato M. Autologous chondrocyte implantation. Operative Techniques in Orthopedics, 2011: 11-2, 115-131, [DOI: 10.1016/S1048-6666(01)80021-5]

98 **Meisel HJ**, Ganey T, Hutton WC, Libera J, Minkus Y, Alasevic O. Clinical experience in cell-based therapeutics: intervention and outcome. *Eur Spine J* 2006; **15** Suppl 3: S397-S405 [PMID: 16850291 DOI: 10.1007/s00586-006-0169-x]

99 **Malda J**, van den Brink P, Meeuwse P, Grojec M, Martens DE, Tramper J, Riesle J, van Blitterswijk CA. Effect of oxygen tension on adult articular chondrocytes in microcarrier bioreactor culture. *Tissue Eng* 2004; **10**: 987-994 [PMID: 15363156 DOI: 10.1089/ten.2004.10.987]

100 **Pettersson S**, Wetterö J, Tengvall P, Kratz G. Cell expansion of human articular chondrocytes on macroporous gelatine scaffolds-impact of microcarrier selection on cell proliferation. *Biomed Mater* 2011; **6**: 065001 [PMID: 21959554 DOI: 10.1088/1748-6041/6/6/065001]

101 **Evans CH**, Kraus VB, Setton LA. Progress in intra-articular therapy. *Nat Rev Rheumatol* 2014; **10**: 11-22 [PMID: 24189839 DOI: 10.1038/nrrheum.2013.159]

102 **Lieberman JR**, Ghivizzani SC, Evans CH. Gene transfer approaches to the healing of bone and cartilage. *Mol Ther* 2002; **6**: 141-147 [PMID: 12161179 DOI: 10.1006/mthe.2000.0663]

103 **Robbins PD**, Evans CH, Chernajovsky Y. Gene therapy for arthritis. *Gene Ther* 2003; **10**: 902-911 [PMID: 12732875 DOI: 10.1038/sj.gt.3302040]

104 **Lee DK**, Choi KB, Oh IS, Song SU, Hwang S, Lim CL, Hyun JP, Lee HY, Chi GF, Yi Y, Yip V, Kim J, Lee EB, Noh MJ, Lee KH. Continuous transforming growth factor beta1 secretion by cell-mediated gene therapy maintains chondrocyte redifferentiation. *Tissue Eng* 2005; **11**: 310-318 [PMID: 15738684 DOI: 10.1089/ten.2005.11.310]

105 **Lee KH**, Song SU, Hwang TS, Yi Y, Oh IS, Lee JY, Choi KB, Choi MS, Kim SJ. Regeneration of hyaline cartilage by cell-mediated gene therapy using transforming growth factor beta 1-producing fibroblasts. *Hum Gene Ther* 2001; **12**: 1805-1813 [PMID: 11560773 DOI: 10.1089/104303401750476294]

106 **Song SU**, Hong YJ, Oh IS, Yi Y, Choi KB, Lee JW, Park KW, Han JU, Suh JK, Lee KH. Regeneration of hyaline articular cartilage with irradiated transforming growth factor beta1-producing fibroblasts. *Tissue Eng* 2004; **10**: 665-672 [PMID: 15265284 DOI: 10.1089/1076327041348275]

**P-Reviewer:** Kindy MS, Meinhold CL **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Cells from hChonJb#7 WCB**

**Cells from hChonJ WCB**

**Culture hChonJb#7**

**Culture hChonJ**

**Cell Harvest**

**Cell Harvest**

**Cryopreserve**

-------------------------

**Cryopreserve**

**Release Testing**

**In-Process Testing**

**Irradiate at 70 Gy**

**Release Testing**

**Mix at 3:1 ratio**

**Prepare Protocol Specified Dose (cells/ml) and Samples**

**Ship to Clinical Site**

**Figure 1 Schematic figure of TG-C manufacturing.**

**Table 1 Current cell mediated gene therapy protocols in clinical and R and D stages**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Target disease** | **Stage** | **Gene modification** | **Target cell** | **Ref.** |
| Hemophilia A | Preclinical | Oct4, Sox2, Klf4 | Fibroblast | Xu *et al*[40], 2008  |
| ALS | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Dimos *et al*[55], 2008 |
| Alzheimer | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Israel *et al*[46], 2012  |
| ALS | Preclinical | Oct4, Sox2, Klf4 | Fibroblast | Chen *et al*[54], 2014  |
| Cardiac Failure | Preclinical | Gata4, Mef2c, Tbx4 | Fibroblast | Ikeda *et al*[22], 2010  |
| Diabetes | Preclinical | Oct4, Sox2, Klf4 | Fibroblast | Zhang *et al*[24], 2009  |
| Schizophrenia | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast with 15q11.2 del | Yoon *et al*[12], 2014  |
| Barth Syndrome | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Wang *et al*[55], 2014  |
| Parkinson’s Disease | Preclinical | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Chung *et al*[50], 2013  |
| Macular Degeneration | Phase I | Oct4, Sox2, Klf4, c-Myc | Fibroblast | Kamao *et al*[14], 2014  |
| Degenerative Arthritis | Phase II/III | TGF-β1 | Chondrocyte | Ha *et al*[15], 2012  |
| X-linked Adrenoleukodystrophy | In the clinic | ABCD1 | CD34+ Bone Marrow cell | Cartier *et al*[36], 2009  |
| Wiskott-Aldrich Syndrome | In the clinic | WASP | CD34+ Bone Marrow cell | Aiuti *et al*[35], 2013  |
| Metachromatic Leukodystrophy | In the clinic | ARSA | CD34+ Bone Marrow cell | Biffi *et al*[37], 2013  |

**Table 2 Different types of production methods based on cells needed per batch**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cells/lot (billions) | **Cell culture** | **Harvest** | **Filling** | **Freezing** |
| 1 | T175 Flask or Hyperflask, 10 Layer cell factory | Bucket Centrifugation | Hand/ Manual Fill | Bench top Control Rate Freezer |
| 10  | 10 Layer cell Factory, Hyperstack-12, Xpansion systems | Bucket Centrifugation | Semi automated fill machine or hand/manual fill | Bench top Control Rate Freezer |
| 50 | Hyperstack or Xpansion, Cell Cube | Tangential Flow Filtration, continuous centrifugation | Automated Fill Machine | Large Scale Control Rate Freezer |
| 100 | Factory automation of Xpansion or Hyperstack technologies 41. Assawachananont J, Mandai M, Okamoto S, Yamada C, Eiraku M, Yonemura S, Sasai Y and Takahashi M: Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheet into retinal degenerative mice, Stem Cell Reports, 2-5, 662-674, 2014 [PMID: 24936453 DOI: 10.1016/j.stemcr.2014.03.011] (other 2D platforms) | Tangential Flow Filtration of continuous Centrifugation | Automated Fill Machine | Large Scale Control Rate Freezer |
| 500 | Bioreactors using microcarriers | Continuous Centrifugation | Automated Fill Machine | Scale out Large Scale Control Rate Freezer |

**Table 3 Suggested release tests advised by Food and Drug Administration for cell product**

|  |  |  |
| --- | --- | --- |
| **Category** | **Test** | **Key measurement** |
| Sterility | Sterility Mycoplasma | Microbiological testingAfter pooling of cultures but before washing |
| Identity | Identity | cell identity and assess heterogeneity |
| Purity | Impurity Endotoxin | Residuals contaminantsContaminants during the process |
| Potency | Specific to product  | relevant function of the cells |
| Other Testing | General safetyViabilityCell number | Cellular therapy products are exemptGenerally > 70%Minimum and maximum cell number |
| Title 21 of the code of federal regulations applied to cell therapy productsThe tissue rules: part 1271The biologics requirements: Part 600 and 610The investigational new drug requirements: part 312The drug manufacturing requirements: Parts 211 and 212 |

**Table 4 TG-C release test**

|  |  |  |
| --- | --- | --- |
| Test | Method | Specification |
| Release tests and specifications for hChonJ cell |
| Identification - Cell Growth and Morphology | Visual (Test Code 30117) | Fibroblast-like: spindle shaped/bipolar or multipolar cells |
| Viability | Trypan blue dye exclusion(Test Code 30458) | > 70% |
| Mycoplasma | 1993 Points to Consider(Test Code 30055) | Negative  |
| Rat Antibody Production (RAP) Test | *In vivo* and ELISA(Test Code 30163) | Negative |
| Sterility (Direct Inoculation Method) | 21 CFR 610.12(Test Code 30744) | Negative |
| Endotoxin | LAL (Test Code 37653) | < 5 EU/mL |

|  |
| --- |
| Release Tests and Specifications for hChonJb#7 Cell |
| Identity - Cell Growth and Morphology | Visual (Test Code 30117) | Epithelial-like: fried egg or polygonal-shaped appearance |
| - Type II collagen assay | RT-PCR (Test Code 30412) | Type II collagen present |
| - TGF-β1 presence | PCR (Test Code 30959) | TGF-β1 Present |
| Potency (TGF-β1 Assay) | ELISA (Test Code 30444) | 1-50 ng/105 cells/24 h |
| Viability | Trypan blue dye exclusion(Test Code 30458) | > 70% |
| RCR | Co-culture of end of production cells (Test Codes 30628) | Negative |
| Supernatant amplification(Test Code 30633) | Negative |
| Mycoplasma | 1993 Points to Consider(Test Code 30055) | Negative |
| Rat Antibody Production | *In vivo* and ELISA (Test Code 30163) | Negative |
| Endotoxin | LAL (Test Code 37653) | < 5 EU/mL |
| Sterility  | 21 CFR 610.12(Test Code 30744) | Negative |